Local ablation of pancreatic tumors: State of the art and future perspectives

Table 3 Sample size, overall survival, major complication rate, minor complication rate, and mortality rate in pancreatic cancer treated with irreversible electroporation

Ref.	Sample size	Overall survival	Major complication rate	Minor complication rate	Mortality rate
Vroomen et al[14], 2017	25	-	8%	20%	0%
Martin et al[19], 2015	200	24.9 mo (range, 4.9–85 mo)	18.50%	50,5%	2%
Martin et al[20], 2013	54	20 mo	24%	55,5%	2%
Lambert et al[23], 2016	21	10.2 mo	23.80%	-	0%
Yan et al[24], 2016	25	-	36%	16%	0%
Scheffer et al[26], 2017	25	11 mo	40%	40%	0%
Ruarus et al[65], 2020	50	11.6 mo (no induction chemotherapy or gemcitabine-based induction chemotherapy) and 14.9 mo (FOLFIRINOX)	42%	28%	2%
van Veldhuisen et al[66], 2020	30	17.0 (range, 5-35 mo)	20%	23%	0%
Narayananet al[67], 2017	50	27 mo	20%	-	0%
Liu et al[68], 2019	54	16.2 and 20.3 mo in the IRE and IRE + chemo groups	7.40%	81%	0%

IRE: Irreversible electroporation.